Abstract: Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.
Type:
Grant
Filed:
July 10, 2017
Date of Patent:
May 24, 2022
Assignee:
MeMed Diagnostics Ltd.
Inventors:
Eran Eden, Kfir Oved, Assaf Cohen-Dotan, Roy Navon, Olga Boico, Meital Paz
Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
Type:
Grant
Filed:
June 7, 2019
Date of Patent:
May 17, 2022
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov, Pankaj Gupta
Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
May 10, 2022
Assignee:
Cell Design Labs, Inc.
Inventors:
Amy Gilbert, Vladimir Slepushkin, Peter Emtage, Anselm Levskaya, Spencer Scott
Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
Type:
Grant
Filed:
January 29, 2021
Date of Patent:
May 3, 2022
Assignee:
Altor Bioscience, LLC.
Inventors:
Hing C. Wong, Warren Marcus, Bai Liu, Wenxin Xu, Robert G. Newman, Karen Kage, Lijing You, Peter Rhode, Patrick Soon-Shiong
Abstract: The present invention refers to compounds of the carotenoid class, such as lycopene or lacto-lycopene, for their use in the treatment and/or prevention of toxicity caused by antitumor drugs, as well as their use in the treatment or remission of tumors in combination with antitumor drugs. Finally, the present invention refers to the combination of the above set forth compounds and drugs with antitumor action.
Type:
Grant
Filed:
January 15, 2018
Date of Patent:
May 3, 2022
Assignee:
ASSOCIAZIONE ONCOLOGICA MILANESE AMO LA VITA ONLUS
Inventors:
Mauro Moroni, Paolo Pedrazzoli, Marco Giulio Giuseppe Pirovano
Abstract: Disclosed herein are methods for treating subjects having rheumatoid arthritis (RA) with a human anti-interleukin 6 (IL-6) antibody, or antigen-binding portion thereof.
Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
Type:
Grant
Filed:
September 11, 2019
Date of Patent:
May 3, 2022
Assignee:
Eli Lilly and Company
Inventors:
Stephen J Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
April 26, 2022
Assignee:
CEDARS-SINAI MEDICAL CENTER
Inventors:
Kathrin S. Michelsen, Stephan R. Targan
Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
April 26, 2022
Assignee:
Pfizer Inc.
Inventors:
Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
Abstract: [Problem] To provide a nucleic acid expected to be useful for treating mite allergy. [Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.
Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
April 19, 2022
Assignee:
Ferring B.V.
Inventors:
Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
Abstract: The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyimide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
April 19, 2022
Assignees:
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, ENIEGRION INC
Inventors:
Thomas H. Fischer, E. Stan Eskridge, William M. Malloy, Malloy Evans
Abstract: Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
April 12, 2022
Assignee:
Kindred Biosciences, Inc.
Inventors:
Shyr Jiann Li, Lam Nguyen, Lan Yang, Hangjun Zhan
Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Type:
Grant
Filed:
December 2, 2020
Date of Patent:
April 5, 2022
Assignees:
Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
Inventors:
Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill cancer cells that express TLR9 on their surface. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a TLR9-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
March 29, 2022
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Inventors:
Daniel Abate-Daga, Alan F. List, Sheng Wei
Abstract: Disclosed are compositions and methods for stimulating immune responses. More particularly, these compositions and methods involve the use of an inhibitor of IL-25 function and an immune stimulator that stimulates an immune response to a target antigen for stimulating protective or therapeutic immune responses to a target antigen. The compositions and methods of the present invention are particularly useful in the prevention and treatment of infections and cancers.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
March 29, 2022
Assignee:
THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Inventors:
Ronald James Jackson, Charani Ranasinghe
Abstract: Disclosed are methods for diagnosing a myelodysplastic syndrome (MDS) in a subject. In some embodiments, the method involves assaying a sample from the subject to detect inflammasome activation, wherein an increase in inflammasome activation in the sample compared to a control is an indication of MDS in the subject. The disclosed methods can further involve treating the subject for MDS if an increase in inflammasome activation is detected.
Type:
Grant
Filed:
November 11, 2019
Date of Patent:
March 22, 2022
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.